Want to see JP:4553 full AI Analyst Report?
4553 Stock Chart & Stats
¥3620.00
-¥90.00(-2.71%)
At close: 4:00 PM EST
¥3620.00
-¥90.00(-2.71%)
Day’s Range― - ―
52-Week Range¥2,764.00 - ¥4,490.00
Previous CloseN/A
Volume116.60K
Average Volume (3M)112.31K
Market Cap
¥193.66B
Enterprise Value¥375.50K
Total Cash (Recent Filing)¥42.23B
Total Debt (Recent Filing)¥229.93B
Price to Earnings (P/E)23.4
Beta0.47
Next Earnings
Nov 16, 2026EPS Estimate
101.18Next Dividend Ex-DateN/A
Dividend Yield2.03%
Share Statistics
EPS (TTM)167.96
Shares Outstanding51,516,000
10 Day Avg. Volume138,760
30 Day Avg. Volume112,306
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)1.11
Price to Sales (P/S)0.72
P/FCF Ratio24.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,600.00Price Target Upside54.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)465.86
Revenue Forecast (FY)¥305.91B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthContinued revenue expansion indicates sustained demand for Towa’s generic medicines and broadens the company’s revenue base. Growth provides operating scale and supports future product launches, although profitability must improve for this benefit to translate into stronger returns.
Stable Gross MarginA stable gross margin suggests the company retains relatively consistent production economics and pricing discipline despite operating in regulated generic pharmaceuticals. This provides a durable base for recovery if cost pressures ease and product volumes continue to grow.
Broad Generic PortfolioA broad portfolio across therapeutic areas diversifies reliance on individual products and supports recurring demand from hospitals, clinics, and pharmacies. Japan’s established generic-drug distribution system can provide durable market access as branded medicines lose exclusivity.
Bears Say
Profitability CompressionSharp declines in net and EBIT margins show that revenue growth is not converting efficiently into earnings. With TTM net income well below FY2025, sustained cost pressure or unfavorable operating factors could limit reinvestment and weaken shareholder returns.
Elevated LeverageHigher debt relative to equity increases financial obligations while profitability and ROE are already depressed. This reduces balance-sheet flexibility, potentially constraining investment in manufacturing, product development, and supply resilience if earnings remain weak.
Weak Free Cash FlowThin and volatile free cash flow indicates weak conversion of accounting earnings into surplus cash after investment needs. This can make debt reduction, dividends, and sustained product or capacity investment more dependent on financing or improved execution.
Towa Pharmaceutical Co News
4553 FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was ¥2764.00 and its highest was ¥4490.00 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is ¥193.66B.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 16, 2026 which is in 78 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported ¥112.36 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd pays a Semiannually dividend of ¥40 which represents an annual dividend yield of 2.03%. See more information on Towa Pharmaceutical Co Ltd dividends here
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate is 101.18.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of ¥112.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.205%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4553
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
4553 Stock 12 Month Forecast
Average Price Target
¥5,600.00
▲(54.70% Upside)
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―